BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β‐secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cerebrospinal fluid (CSF) sampling in Japanese elderly...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2017-11, Vol.57 (11), p.1460-1471
Hauptverfasser:	Sakamoto, Kei, Matsuki, Shunji, Matsuguma, Kyoko, Yoshihara, Tatsuya, Uchida, Naoki, Azuma, Fumihiko, Russell, Muir, Hughes, Glen, Haeberlein, Samantha Budd, Alexander, Robert C., Eketjäll, Susanna, Kugler, Alan R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Alzheimer disease Alzheimer Disease - drug therapy Amyloid beta-Peptides - metabolism Amyloid beta-Protein Precursor - metabolism Amyloid Precursor Protein Secretases - antagonists & inhibitors Amyloid Precursor Protein Secretases - metabolism amyloid‐β peptides Asian Continental Ancestry Group Aspartic Acid Endopeptidases - antagonists & inhibitors BACE1 protein‐human Brain - metabolism Cerebrospinal Fluid - metabolism cerebrospinal fluid proteins clinical trials Double-Blind Method Female Half-Life Healthy Volunteers Humans Imidazoles - therapeutic use Japanese lanabecestat, AZD3293 Male Middle Aged Peptide Fragments - metabolism Plasma - metabolism Spiro Compounds - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!